Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer. - Wikidata - wikimedia - TriplyDB

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

http://www.wikidata.org/entity/Q33371394

about

A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver.Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.

P2860

Q37216654-2B9DB134-E9B2-4100-9BDD-0FC320050D63 Q39482884-D681C0FB-1D85-4B07-9649-4C603207F764

P2860

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

http://www.wikidata.org/entity/Q33371394

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@ast

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@en

type

label

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@ast

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@en

prefLabel

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@ast

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@en

P1433

Q33371394-74416962-D324-4B50-A924-E461EA598F4C

P1476

Q33371394-064C7B9E-F851-4837-8271-D0EAA9292DC8

P2093

Q33371394-1A710617-76A5-4A4E-86A1-2CAFD51654FB

Q33371394-1FFA70F0-E6E4-40D8-AC0A-ECC103DD7FE5

Q33371394-3F3F45AE-D226-43D8-A3BE-FFEF89E049A1

Q33371394-4431F18B-2A78-4453-8215-CD3B9F0D9A9B

Q33371394-6F519E14-CB88-4178-9399-DD8DF7D41409

Q33371394-72393120-B760-44A6-BA4F-DB78FA56F114

Q33371394-80A53B5E-A84C-401C-8CA9-D31DAD13E2D6

Q33371394-AD4C563F-5945-4C52-97AC-D61DC28AC734

Q33371394-BAEAD706-6FF8-4736-AC92-672BA87D1D97

Q33371394-BB473C98-C9BC-4519-B3E0-04C35A5B2892

P2860

Q33371394-467ADB2B-D8DA-4A92-945C-79A3545E0DF6

Q33371394-5C100E7C-C18E-4FE9-9E1E-9755912E6500

Q33371394-63DC296A-DF1F-49C4-8326-51B8B5FB7B4E

Q33371394-79943AD5-16EC-481D-8C2E-3D7FFECFB305

Q33371394-7A37776C-E082-4D7C-9ABF-38D575619886

Q33371394-7E73204E-5AA1-4F2B-B7E0-35ED2AB9BAED

Q33371394-C3D148A3-2C46-4F56-A013-BFD32EB4A358

Q33371394-E50550E8-1B18-4C16-B9CD-30A8A5D8FEF9

Q33371394-ED173CA6-32D1-4917-9844-3401E116D133

Q33371394-FB70BF56-D20B-4372-8936-E60F4A85B5BC

P304

Q33371394-E2C9D3E8-F9BA-4F97-A6C2-02C944D513A8

P31

Q33371394-E03CBB91-0551-4078-B1C1-BE2488C85C08

P356

Q33371394-4A87C3A1-A177-4527-AD54-056517737C35

P433

Q33371394-2392C5B5-42B0-4525-B75B-F1A97BB14836

P478

Q33371394-128F01BA-A664-4A1A-80AD-EF64D4802964

P50

Q33371394-C6D97E44-98C7-40C2-8240-AEA832CE10FB

Q33371394-E1D6D758-724B-45CD-A88B-2049CC08D707

P577

Q33371394-95CA70CB-CEF3-4DC3-82F4-B97C9A6F83AC

P698

Q33371394-97A70E25-5B88-4AA9-8C48-38B14DF0F85C

P356

JOC.2006.18.2.192

P1433

Journal of Chemotherapy

P1476

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

@en

P2093

A Koutras

http://www.w3.org/2001/XMLSchema#string

A Onyenadum

http://www.w3.org/2001/XMLSchema#string

C Markopoulos

http://www.w3.org/2001/XMLSchema#string

D Bafaloukos

http://www.w3.org/2001/XMLSchema#string

E Tzorakoelefterakis

http://www.w3.org/2001/XMLSchema#string

G Aravantinos

http://www.w3.org/2001/XMLSchema#string

H Bacoyiannis

http://www.w3.org/2001/XMLSchema#string

H Gogas

http://www.w3.org/2001/XMLSchema#string

H P Kalofonos

http://www.w3.org/2001/XMLSchema#string

Hellenic Cooperative Oncology Group

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.

Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.

Cancer statistics, 2000.

Advanced breast cancer: a phase II trial with gemcitabine.

Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer.

Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.

P304

192-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/JOC.2006.18.2.192

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

George Fountzilas

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16736889

http://www.w3.org/2001/XMLSchema#string